Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

Fig. 1

Rate of clinically significant exacerbations by comorbidity category. The rate of clinically significant exacerbations was analyzed using a negative binomial generalized linear model with a log-link function, including log of time on treatment as an offset variable. p-interaction < 0.1. AR allergic rhinitis/hay fever; CI confidence interval; GERD gastroesophageal reflux disease; mepo mepolizumab

Back to article page